688506 百利天恒
已收盘 11-13 15:00:00
资讯
新帖
简况
百利天恒最新公告：注射用伦康依隆妥单抗纳入国家医保目录
证券之星 · 16:31
百利天恒最新公告：注射用伦康依隆妥单抗纳入国家医保目录
百利天恒：宜泽康®成功纳入国家医保目录
格隆汇 · 11-14 12:03
百利天恒：宜泽康®成功纳入国家医保目录
百利天恒董事长朱义：中国创新药结构性优势正被全球验证，未来十年仍将具备竞争力
长三角资本局 · 11-13 17:22
百利天恒董事长朱义：中国创新药结构性优势正被全球验证，未来十年仍将具备竞争力
百利天恒（688506）11月11日主力资金净卖出1670.95万元
证券之星 · 11-12
百利天恒（688506）11月11日主力资金净卖出1670.95万元
百利天恒（688506）11月10日主力资金净买入2328.27万元
证券之星 · 11-11
百利天恒（688506）11月10日主力资金净买入2328.27万元
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司关于召开2026年第三季度业绩说明会的公告》
证券之星 · 11-10
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司关于召开2026年第三季度业绩说明会的公告》
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司关于召开2026年第三季度业绩说明会的公告》
证券之星 · 11-09
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司关于召开2026年第三季度业绩说明会的公告》
百利天恒（688506）11月6日主力资金净买入1613.62万元
证券之星 · 11-07
百利天恒（688506）11月6日主力资金净买入1613.62万元
百利天恒（688506）披露2026年第三季度报告，11月2日股价上涨3.66%
证券之星 · 11-02
百利天恒（688506）披露2026年第三季度报告，11月2日股价上涨3.66%
股市必读：百利天恒三季报 - 第三季度单季净利润同比增长49.54%
证券之星 · 11-02
股市必读：百利天恒三季报 - 第三季度单季净利润同比增长49.54%
百利天恒(688506)9月30日股东户数0.95万户，较上期增加5.1%
证券之星 · 10-31
百利天恒(688506)9月30日股东户数0.95万户，较上期增加5.1%
百利天恒（688506）10月30日主力资金净卖出686.34万元
证券之星 · 10-31
百利天恒（688506）10月30日主力资金净卖出686.34万元
百利天恒：第三季度净利润同比增长49.54%
格隆汇 · 10-30
百利天恒：第三季度净利润同比增长49.54%
百利天恒自历史高点跌42% 招商证券在”大顶”强烈推荐
中金财经 · 10-28
百利天恒自历史高点跌42% 招商证券在”大顶”强烈推荐
10月26日百利天恒跌5.23%，创金合信医疗保健股票A基金重仓该股
证券之星 · 10-26
10月26日百利天恒跌5.23%，创金合信医疗保健股票A基金重仓该股
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告》
证券之星 · 10-26
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告》
百利天恒最新公告：T-BrenIII期临床试验达主要终点
证券之星 · 10-25
百利天恒最新公告：T-BrenIII期临床试验达主要终点
百利天恒最新公告：双抗ADC新药上市申请获受理
证券之星 · 10-25
百利天恒最新公告：双抗ADC新药上市申请获受理
10月23日百利天恒涨5.73%，中欧医药生物混合发起A基金重仓该股
证券之星 · 10-23
10月23日百利天恒涨5.73%，中欧医药生物混合发起A基金重仓该股
百利天恒涨5.73%，开源证券一个月前给出“买入”评级
证券之星 · 10-23
百利天恒涨5.73%，开源证券一个月前给出“买入”评级
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是丙泊酚乳状注射液、吸入用七氟烷、丙泊酚中/长链脂肪乳注射液、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":250.05,"timestamp":1794553200000,"preClose":252.72,"halted":0,"volume":1046147,"delay":0,"changeRate":-0.0106,"floatShares":413000000,"shares":413000000,"eps":-3.0616,"marketStatus":"已收盘","change":-2.67,"latestTime":"11-13 15:00:00","open":253.31,"high":253.36,"low":248.25,"amount":262000000,"amplitude":0.0202,"askPrice":250.17,"askSize":4,"bidPrice":250.05,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-3.0616,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":5,"adr":0,"adjPreClose":252.72,"symbolType":"stock_kcb","openAndCloseTimeList":[[1794533400000,1794540600000],[1794546000000,1794553200000]],"highLimit":277.99,"lowLimit":227.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":18.89,"roa":"--","roe":"--","epsLYR":-2.61,"committee":-0.290323,"marketValue":103239000000,"turnoverRate":0.0025,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-16。","afterMarket":{"amount":0,"volume":0,"close":250.05,"buyVolume":0,"sellVolume":200,"time":1794555237746,"indexStatus":"已收盘 11-13 15:30:00","preClose":252.72},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1794556800000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":103239000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2683655078","title":"百利天恒最新公告：注射用伦康依隆妥单抗纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683655078","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683655078?lang=zh_cn&edition=full","pubTime":"2026-11-15 16:31","pubTimestamp":1794731474,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司全资子公司自主研发的全球首创双抗ADC药物注射用伦康依隆妥单抗，上市首年即通过国家医保谈判，成功纳入《国家医保目录(2026版)》，协议有效期自2027年1月1日至2028年12月31日，支付范围限既往经至少二线系统化疗且使用过PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111500004474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683682444","title":"百利天恒：宜泽康®成功纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683682444","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683682444?lang=zh_cn&edition=full","pubTime":"2026-11-14 12:03","pubTimestamp":1794629020,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["91194","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683576506","title":"百利天恒董事长朱义：中国创新药结构性优势正被全球验证，未来十年仍将具备竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2683576506","media":"长三角资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683576506?lang=zh_cn&edition=full","pubTime":"2026-11-13 17:22","pubTimestamp":1794561720,"startTime":"0","endTime":"0","summary":"圆桌讨论上，百利天恒创始人、董事长朱义表示，中国创新药产业长期积累形成的结构性优势，正在被全球市场深刻理解和验证。朱义表示，过去较长一段时间，中国创新药的优势首先体现在单个创新品种的出现，随后逐渐发展到技术平台层面。朱义强调，研发人才、临床资源、监管体系以及产业组织能力相互结合，构成了中国创新药产业独特的竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/csjzbj/2026-11-13/doc-iniyqsmv0984114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688506","KURE","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682536638","title":"百利天恒（688506）11月11日主力资金净卖出1670.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682536638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682536638?lang=zh_cn&edition=full","pubTime":"2026-11-12 08:33","pubTimestamp":1794443591,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月11日收盘，百利天恒报收于255.58元，下跌1.27%，换手率0.25%，成交量1.02万手，成交额2.62亿元。近5日资金流向一览见下表：百利天恒融资融券信息显示，融资方面，当日融资买入1843.01万元，融资偿还1344.78万元，融资净买入498.23万元。百利天恒主营业务：药品的研发、生产与营销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200006622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682328855","title":"百利天恒（688506）11月10日主力资金净买入2328.27万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682328855","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682328855?lang=zh_cn&edition=full","pubTime":"2026-11-11 08:24","pubTimestamp":1794356685,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月10日收盘，百利天恒报收于258.88元，下跌2.84%，换手率0.43%，成交量1.77万手，成交额4.57亿元。近5日资金流向一览见下表：百利天恒融资融券信息显示，融资方面，当日融资买入2493.94万元，融资偿还2439.28万元，融资净买入54.67万元。百利天恒主营业务：药品的研发、生产与营销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100013407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682633347","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682633347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682633347?lang=zh_cn&edition=full","pubTime":"2026-11-10 02:56","pubTimestamp":1794250605,"startTime":"0","endTime":"0","summary":"截至2026年11月9日收盘，百利天恒报收于266.44元，上涨0.84%，换手率0.35%，成交量1.43万手，成交额3.83亿元。公司公告汇总：百利天恒将于2026年11月18日15:00-16:00召开2026年第三季度业绩说明会，通过上证路演中心网络互动方式进行。投资者可于11月11日至17日通过上证路演中心或公司邮箱ir@baili-pharm.com提前提问。说明会结束后可通过该平台查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111000002984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682825613","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682825613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682825613?lang=zh_cn&edition=full","pubTime":"2026-11-09 01:41","pubTimestamp":1794159667,"startTime":"0","endTime":"0","summary":"截至2026年11月6日收盘，百利天恒报收于264.23元，上涨0.43%，换手率0.4%，成交量1.65万手，成交额4.45亿元。当日关注点交易信息汇总：11月6日主力资金净流入1613.62万元，占总成交额3.63%。公司公告汇总：百利天恒将于2026年11月18日15:00-16:00召开2026年第三季度业绩说明会，通过上证路演中心网络互动方式进行。投资者可于11月11日至17日通过上证路演中心或公司邮箱ir@baili-pharm.com提前提问。说明会结束后可通过该平台查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900000489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681818737","title":"百利天恒（688506）11月6日主力资金净买入1613.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681818737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681818737?lang=zh_cn&edition=full","pubTime":"2026-11-07 09:06","pubTimestamp":1794013580,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月6日收盘，百利天恒报收于264.23元，上涨0.43%，换手率0.4%，成交量1.65万手，成交额4.45亿元。近5日资金流向一览见下表：百利天恒融资融券信息显示，融资方面，当日融资买入2682.24万元，融资偿还3393.75万元，融资净偿还711.51万元。百利天恒主营业务：药品的研发、生产与营销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110700010094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680561077","title":"百利天恒（688506）披露2026年第三季度报告，11月2日股价上涨3.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680561077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680561077?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:22","pubTimestamp":1793618546,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘，百利天恒报收于253.01元，较前一交易日上涨3.66%，最新总市值为1044.61亿元。近日，四川百利天恒药业股份有限公司披露《2026年第三季度报告》。公告显示，本报告期营业收入为1,906,548,742.68元，同比增长0.63%；归属于上市公司股东的净利润为932,295,639.11元，同比增长49.54%；研发投入合计884,102,752.98元，同比增长20.49%。年初至报告期末，营业收入为2,093,883,517.81元，同比增长1.35%；归属于上市公司股东的净利润为-704,920,538.61元；经营活动产生的现金流量净额为-2,167,924,116.74元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200029064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680788739","title":"股市必读：百利天恒三季报 - 第三季度单季净利润同比增长49.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680788739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680788739?lang=zh_cn&edition=full","pubTime":"2026-11-02 06:56","pubTimestamp":1793573772,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年第三季度单季度归母净利润9.32亿元，同比增长49.54%；前三季度归母净利润为-7.05亿元，同比下降42.55%。四川百利天恒药业股份有限公司2026年第三季度报告2026年第三季度营业收入19.07亿元，同比增长0.63%；归母净利润9.32亿元，同比增长49.54%；研发投入8.84亿元，同比增长20.49%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200001825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679278098","title":"百利天恒(688506)9月30日股东户数0.95万户，较上期增加5.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679278098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679278098?lang=zh_cn&edition=full","pubTime":"2026-10-31 17:18","pubTimestamp":1793438319,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百利天恒披露，截至2026年9月30日公司股东户数为9538.0户，较6月30日增加463.0户，增幅为5.1%。在化学制药行业个股中，百利天恒股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.98万户。从股价来看，2026年6月30日至2026年9月30日，百利天恒区间跌幅为17.7%，在此期间股东户数增加463.0户，增幅为5.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100033400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679260372","title":"百利天恒（688506）10月30日主力资金净卖出686.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679260372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679260372?lang=zh_cn&edition=full","pubTime":"2026-10-31 08:19","pubTimestamp":1793405994,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月30日收盘，百利天恒报收于244.07元，上涨1.37%，换手率0.47%，成交量1.93万手，成交额4.76亿元。近5日资金流向一览见下表：百利天恒融资融券信息显示，融资方面，当日融资买入2801.47万元，融资偿还4358.08万元，融资净偿还1556.6万元。百利天恒主营业务：药品的研发、生产与营销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100018215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679213685","title":"百利天恒：第三季度净利润同比增长49.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679213685","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679213685?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:20","pubTimestamp":1793359228,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678774452","title":"百利天恒自历史高点跌42% 招商证券在”大顶”强烈推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2678774452","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678774452?lang=zh_cn&edition=full","pubTime":"2026-10-28 17:21","pubTimestamp":1793179262,"startTime":"0","endTime":"0","summary":"中国经济网北京10月28日讯 百利天恒 今日收报238.32元，跌幅3.51%。 2025年9月8日，百利天恒股价盘中创上市以来高点414.02元。百利天恒股价较高点跌幅达42.438%。 国泰海通证券股份有限公司研究员余文心、廖博闻2025年9月12日发布研报《百利天恒：WCLC上公布全球BIC数据 IZA-BREN有望冲击一线市场》称，维持增持评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20261028/32410065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1147","91194","BK0010","BK0012","BK0239","BK0028","BK0183","688506","BK0276","BK1564","BK0188","600999","06099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678163825","title":"10月26日百利天恒跌5.23%，创金合信医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678163825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678163825?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:37","pubTimestamp":1793003856,"startTime":"0","endTime":"0","summary":"证券之星消息，10月26日百利天恒跌5.23%，收盘报253.5元，换手率0.56%，成交量2.33万手，成交额6.1亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为创金合信基金的创金合信医疗保健股票A。创金合信医疗保健股票A目前规模为1.31亿元，最新净值1.7668，较上一交易日上涨3.6%，近一年下跌13.81%。创金合信医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600021929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678135272","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678135272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678135272?lang=zh_cn&edition=full","pubTime":"2026-10-26 01:17","pubTimestamp":1792948628,"startTime":"0","endTime":"0","summary":"治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告四川百利天恒药业股份有限公司自主研发的宜泽康治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性HR+HER2-乳腺癌的药品上市申请已获国家药品监督管理局药品审评中心受理。目前该药物已有2项适应症获批上市，另有2项适应症上市申请已获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678187687","title":"百利天恒最新公告：T-BrenIII期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2678187687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678187687?lang=zh_cn&edition=full","pubTime":"2026-10-25 16:31","pubTimestamp":1792917072,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)在经曲妥珠单抗和紫杉烷类治疗失败的不可切除局部晚期或转移性HER2阳性乳腺癌III期临床试验中，经独立数据监查委员会判断，预设期中分析达到无进展生存期主要终点。该药正在国内外开展21项临床试验，其中2项适应症已被国家药监局药品审评中心纳入突破性治疗品种名单。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500004309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678503187","title":"百利天恒最新公告：双抗ADC新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2678503187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678503187?lang=zh_cn&edition=full","pubTime":"2026-10-25 16:29","pubTimestamp":1792916986,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的全球首创双抗ADC药物“伦康依隆妥单抗”用于治疗EGFR-TKI耐药EGFR突变非小细胞肺癌的药品上市申请获国家药监局药审中心正式受理。该药为全球首个且唯一获批上市的EGFR×HER3双抗ADC，此次受理基于III期临床试验期中分析结果，已达到无进展生存期主要终点。截至目前，该药已有2项适应症获批上市，2项适应症上市申请获受理。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500004307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677944916","title":"10月23日百利天恒涨5.73%，中欧医药生物混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677944916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677944916?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:42","pubTimestamp":1792744933,"startTime":"0","endTime":"0","summary":"证券之星消息，10月23日百利天恒涨5.73%，收盘报267.5元，换手率0.54%，成交量2.21万手，成交额5.72亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为中欧基金的中欧医药生物混合发起A。中欧医药生物混合发起A目前规模为0.22亿元，最新净值1.0036，较上一交易日下跌4.02%。中欧医药生物混合发起A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300030407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000808.SH","91194","BK0239","163118","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677494494","title":"百利天恒涨5.73%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2677494494","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677494494?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:42","pubTimestamp":1792744923,"startTime":"0","endTime":"0","summary":"今日百利天恒涨5.73%，收盘报267.5元。2026年8月28日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《公司信息更新报告：宜泽康商业化元年开启，核心管线进入全球加速期》，该研报对百利天恒给出“买入”评级。研报中预计2026-2028年营业收入分别为24.89/23.81/32.74亿元，PS分别为44.9/47.0/34.1倍，维持“买入”评级。百利天恒个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300030401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794748473653,"stockEarnings":[{"period":"1week","weight":-0.0537},{"period":"1month","weight":0.104},{"period":"3month","weight":-0.172},{"period":"6month","weight":-0.0271},{"period":"1year","weight":-0.3278},{"period":"ytd","weight":-0.2261}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9538人(较上一季度增加5.10%)","perCapita":"43287股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是丙泊酚乳状注射液、吸入用七氟烷、丙泊酚中/长链脂肪乳注射液、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}